On August 19, Spdr S&P Biotech Etf rose 5.02% in regular trading, trading at $168.02/share, with turnover of $1.595 billion.

On the news front, the U.S. biotech sector surged broadly as multiple catalysts converged. Moderna soared over 130% in a single session, Merck gained over 11%, Eli Lilly rose more than 5%, while Pfizer, Novo Nordisk, and AstraZeneca each climbed approximately 3%. Accelerating large-cap pharma M&A activity combined with continued AI-driven drug discovery order flow boosted upstream life sciences demand, signaling an overall recovery in sector sentiment. Additionally, Regeneron's Libtayo received Health Canada approval for adjuvant treatment of high-risk cutaneous squamous cell carcinoma, further lifting market confidence.

Spdr S&P Biotech Etf seeks to provide investment results that correspond generally to the total return performance of the S&P Biotechnology Select Industry Index, employing a sampling strategy and investing substantially all of its total assets in securities comprising the index.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)